← Leaderboards
George Pappas
Schedule 1 Therapeutics, Inc.
$3,192,104
Attributed
$3,192,104
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,192,104 · 2
By mechanism
R44$2,883,639 · 1
R41$308,465 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Schedule”
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Wally Narajowski$21,300,000
- Sarah Fuller · University Of North Carolina At Chapel Hill$20,582,968
- Paula Gonzalez-Maya · Fundacion Inciensa$17,061,460
- Caroline Sigman · Ccs Associates, Inc.$13,846,650
Research focus
ScheduleAcuteFormulationPrevalenceSpontaneous PainTetrahydrocannabinolDrug DevelopmentFda ApprovedPainPre-Clinical ModelDesignDisabilitySymptomsBehavioralAdverse EffectsClinical ResearchCannabidiolCannabinoidsMigraineCannabisPharmaceutical PreparationsPre-ClinicalDevicesDiagnosis
Grant awards (3)
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics$864,417
R44 · FY2025 · DA · contact PI
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics$2,019,222
R44 · FY2024 · DA · contact PI
Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics$308,465
R41 · FY2020 · DA · contact PI